Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer

Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 67, 7–30 (2017).

Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014).

Wolfgang, C. L. et al. Recent progress in pancreatic cancer. CA Cancer J. Clin. 63, 318–348 (2013).

Oettle, H. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297, 267–277 (2007).

Erkan, M. et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6, 1155–1161 (2008).

Ronnov-Jessen, L., Petersen, O. W. & Bissell, M. J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 76, 69–125 (1996).

Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582 (2016).

von Ahrens, D., Bhagat, T. D., Nagrath, D., Maitra, A. & Verma, A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J. Hematol. Oncol. 10, 76 (2017).

Cirri, P. & Chiarugi, P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 31, 195–208 (2012).

Nair, N. et al. A cancer stem cell model as the point of origin of cancer-associated fibroblasts in tumor microenvironment. Sci. Rep. 7, 6838 (2017).

Richards, K. E. et al. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene 36, 1770–1778 (2017).

De, W. O., Van, B. M., Mareel, M., Hendrix, A. & Bracke, M. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Semin Cancer Biol. 25, 33 (2014).

Yasui, D., Miyano, M., Cai, S., Varga-Weisz, P. & Kohwi-Shigematsu, T. SATB-1 targets chromatin remodelling to regulate genes over long distances. Nature 419, 641–645 (2002).

Cai, S., Han, H. J. & Kohwi-Shigematsu, T. Tissue-specific nuclear architecture and gene expression regulated by SATB-1. Nat. Genet. 34, 42–51 (2003).

Burute, M., Gottimukkala, K. & Galande, S. Chromatin organizer SATB-1 is an important determinant of T-cell differentiation. Immunol. Cell Biol. 90, 852–859 (2012).

Savarese, F. et al. Satb1 and Satb2 regulate embryonic stem cell differentiation and Nanog expression. Genes Dev. 23, 2625–2638 (2009).

Han, H. J., Russo, J., Kohwi, Y. & Kohwi-Shigematsu, T. SATB-1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 452, 187–193 (2008).

Tu, W. et al. Upregulation of SATB-1 promotes tumor growth and metastasis in liver cancer. Liver Int. 32, 1064–1078 (2012).

Hedner, C. et al. SATB-1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma. Virchows Arch. 465, 649–659 (2014).

Cheng, C. et al. Overexpression of SATB-1 is associated with biologic behavior in human renal cell carcinoma. PLOS ONE 9, e97406 (2014).

Wan, F. et al. SATB1 overexpression regulates the development and progression in bladder cancer through EMT. PLOS ONE 10, e117518 (2015).

Mao, L. J. et al. SATB1 promotes prostate cancer metastasis by the regulation of epithelial-mesenchymal transition. Biomed. Pharmacother. 79, 1–8 (2016).

Mir, R., Pradhan, S. J., Patil, P., Mulherkar, R. & Galande, S. Wnt/beta-catenin signaling regulated SATB1 promotes colorectal cancer tumorigenesis and progression. Oncogene 35, 1679–1691 (2016).

Li, Y. C. et al. SATB1 promotes tumor metastasis and invasiveness in oral squamous cell carcinoma. Oral Dis. 23, 247–254 (2017).

Nodin, B., Hedner, C., Uhlen, M. & Jirstrom, K. Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J. Ovarian Res. 5, 24 (2012).

Guo, L., Zheng, J., Yu, T., Liu, Y. & Duo, L. Elevated expression of SATB1 is involved in pancreatic tumorigenesis and is associated with poor patient survival. Mol. Med. Rep. 16, 8842–8848 (2017).

Chen, Z. et al. SATB1 promotes pancreatic cancer growth and invasion depending on MYC activation. Dig. Dis. Sci. 60, 3304–3317 (2015).

Fuyuhiro, Y. et al. Upregulation of cancer-associated myofibroblasts by TGF-beta from scirrhous gastric carcinoma cells. Br. J. Cancer 105, 996–1001 (2011).

Mir, R., Pradhan, S. J. & Galande, S. Chromatin organizer SATB1 as a novel molecular target for cancer therapy. Curr. Drug Targets 13, 1603–1615 (2012).

Kohwi-Shigematsu, T. et al. Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol. 23, 72–79 (2013).

Janssens, R., Struyf, S. & Proost, P. The unique structural and functional features of CXCL12. Cell Mol. Immunol. 15, 299–311 (2018).

Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015).

Qin, X. et al. Cancer-associated fibroblast-derived IL-6 promotes head and neck cancer pogression via the osteopontin-NF-kappa B signaling pathway. Theranostics 8, 921–940 (2018).

Ren, Y. et al. Paracrine and epigenetic control of CAF-induced metastasis: the role of HOTAIR stimulated by TGF-ss1 secretion. Mol. Cancer 17, 5 (2018).

Alba-Castellon, L. et al. Snail1-dependent activation of cancer-associated fibroblast controls epithelial tumor cell invasion and metastasis. Cancer Res. 76, 6205–6217 (2016).

Sleightholm, R. L. et al. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. Pharmacol. Ther. 179, 158–170 (2017).

Seoane, J. & Gomis, R. R. TGF-beta family signaling in tumor suppression and cancer progression. Cold Spring Harb. Perspect. Biol. 9, pii: a022277 (2017).

Dickinson, L. A., Joh, T., Kohwi, Y. & Kohwi-Shigematsu, T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell 70, 631–645 (1992).

Selinger, C. I. et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J. Thorac. Oncol. 6, 1179–1189 (2011).

Zhang, Y. et al. Expression of SATB1 promotes the growth and metastasis of colorectal cancer. PLOS ONE 9, e100413 (2014).

Al-Sohaily, S. et al. Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer. Histopathology 65, 155–163 (2014).

Cheng, C. et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS 118, 855–863 (2010).

Elenbaas, B. & Weinberg, R. A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264, 169–184 (2001).

Paraiso, K. H. & Smalley, K. S. Fibroblast-mediated drug resistance in cancer. Biochem. Pharmacol. 85, 1033–1041 (2013).

Ham, S. L. et al. Three-dimensional tumor model mimics stromal - breast cancer cells signaling. Oncotarget 9, 249–267 (2018).

Jung, K. et al. Targeting CXCR4-dependent immunosuppressive Ly6C(low) monocytes improves antiangiogenic therapy in colorectal cancer. Proc. Natl. Acad. Sci. USA 114, 10455–10460 (2017).

Calinescu, A. A. et al. Survival and proliferation of neural progenitor-derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine-positive feedback mechanism. Clin. Cancer Res. 23, 1250–1262 (2017).

Cho, B. S. et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood 126, 222–232 (2015).

Morimoto, M. et al. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. BMC Cancer 16, 305 (2016).

Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110, 20212–20217 (2013).